Emergent BioSolutions (EBS) Capital Expenditures Growth (1y) (2011 - 2026)
Emergent BioSolutions (EBS) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 8.33% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -19.86% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.95% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 73.63% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -0.19% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -37.60% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -42.11% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Emergent BioSolutions | 261.35 Mn | 120.45 Mn | 137.20 Mn | -27.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.59% |
| Mar 31, 2026 | -33.33% |
| Dec 31, 2025 | -111.76% |
| Sep 30, 2025 | -181.03% |
| Jun 30, 2025 | -76.03% |
| Mar 31, 2025 | 9.09% |
| Dec 31, 2024 | -95.99% |
| Sep 30, 2024 | 131.52% |
| Jun 30, 2024 | -38.89% |
| Mar 31, 2024 | -57.69% |
| Dec 31, 2023 | 151.21% |
| Sep 30, 2023 | -165.95% |
| Jun 30, 2023 | -38.32% |
| Mar 31, 2023 | -75.78% |
| Dec 31, 2022 | -514.00% |
| Sep 30, 2022 | 188.01% |
| Jun 30, 2022 | 4,112.50% |
| Mar 31, 2022 | -0.92% |
| Dec 31, 2021 | 306.19% |
| Sep 30, 2021 | 36.09% |